Lakefront Biotherapeutics (LKFT) Operating Margin (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Operating Margin of 982.92% for Q1 2026, down 77124.0% year-over-year from N/an in Q1 2025, and down 1269.36% quarter-over-quarter from 84.06% in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Operating Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Operating Margin for 13 consecutive years, with 982.92% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin fell 77124.0% year-over-year to 982.92%; the TTM figure through Mar 2026 stood at 36.78% (up 11665.0% YoY), while the FY2025 annual figure was 26.53%, up 9485.0% from the prior year.
- Operating Margin retreated to 982.92% in Q1 2026 per LKFT's latest filing, from 84.06% in the prior quarter.
- Across five years, Operating Margin topped out at 620.0% in Q4 2024 and bottomed at 982.92% in Q1 2026.
- Historically, Operating Margin has averaged 105.06% across 5 years, with a median of 53.07% in 2024.
- Annual changes were most pronounced in 2022 — Operating Margin jumped 273065 bps — and 2026, when it plunged 77124 bps.
- Lakefront Biotherapeutics' Operating Margin stood at 2.21% in 2022, then soared by 8644 bps to 193.5% in 2023, then jumped by 220 bps to 620.0% in 2024, then sank by 86 bps to 84.06% in 2025, then sank by 1269 bps to 982.92% in 2026.
- Business Quant data shows LKFT's Operating Margin at 982.92% in Q1 2026, 84.06% in Q4 2025, and 647.62% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | -358.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -358.92% |
| Mar 31, 2026 | -982.92% |
| Dec 31, 2025 | 84.06% |
| Sep 30, 2025 | -346.51% |
| Jun 30, 2025 | -87.25% |
| Mar 31, 2025 | -211.68% |
| Dec 31, 2024 | 190.13% |
| Sep 30, 2024 | -119.07% |
| Jun 30, 2024 | -403.65% |
| Mar 31, 2024 | -53.07% |
| Dec 31, 2023 | 39.96% |
| Sep 30, 2023 | -23.23% |
| Jun 30, 2023 | -22.49% |
| Mar 31, 2023 | -24.24% |
| Dec 31, 2022 | -2.37% |
| Sep 30, 2022 | -27.58% |
| Jun 30, 2022 | -55.47% |
| Mar 31, 2022 | -15.51% |
| Dec 31, 2021 | -4.95% |
| Sep 30, 2021 | -55.27% |